Biomarkers for Huntington's Disease Improving Clinical Outcomes /
Huntington’s disease (HD) is a fatal, inherited, neurodegenerative disorder, characterized by chorea, motor instabilities, psychiatric manifestations and cognitive decline. Early genetic testing provides an opportunity for clinical interventions aimed at delaying onset and/or slowing progression of...
Đã lưu trong:
| Tác giả của công ty: | |
|---|---|
| Tác giả khác: | , |
| Định dạng: | Điện tử eBook |
| Ngôn ngữ: | Tiếng Anh |
| Được phát hành: |
Cham :
Springer International Publishing : Imprint: Springer,
2023.
|
| Phiên bản: | 1st ed. 2023. |
| Loạt: | Contemporary Clinical Neuroscience,
|
| Những chủ đề: | |
| Truy cập trực tuyến: | https://doi.org/10.1007/978-3-031-32815-2 |
| Các nhãn: |
Thêm thẻ
Không có thẻ, Là người đầu tiên thẻ bản ghi này!
|
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 001 | 978-3-031-32815-2 | ||
| 003 | DE-He213 | ||
| 005 | 20260810114832.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 231012s2023 sz | o |||| 0|eng d | ||
| 020 | |a 9783031328152 |9 978-3-031-32815-2 | ||
| 024 | 7 | |a 10.1007/978-3-031-32815-2 |2 doi | |
| 050 | 4 | |a RC321-580 | |
| 072 | 7 | |a PSAN |2 bicssc | |
| 072 | 7 | |a SCI089000 |2 bisacsh | |
| 072 | 7 | |a PSAN |2 thema | |
| 082 | 0 | 4 | |a 612.8 |2 23 |
| 245 | 1 | 0 | |a Biomarkers for Huntington's Disease |h [electronic resource] : |b Improving Clinical Outcomes / |c edited by Elizabeth A. Thomas, Georgia M. Parkin. |
| 250 | |a 1st ed. 2023. | ||
| 264 | 1 | |a Cham : |b Springer International Publishing : |b Imprint: Springer, |c 2023. | |
| 300 | |a 1 online resource (XVI, 475 p. 42 illus.). |b 39 illus. in color. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 341 | 0 | |b Table of contents navigation |2 onix | |
| 341 | 0 | |b Single logical reading order |2 onix | |
| 341 | 0 | |b Short alternative textual descriptions |2 onix | |
| 341 | 0 | |b Use of color is not sole means of conveying information |2 onix | |
| 341 | 0 | |b Use of high contrast between text and background color |2 onix | |
| 341 | 0 | |b Next / Previous structural navigation |2 onix | |
| 341 | 0 | |b All non-decorative content supports reading without sight |2 onix | |
| 347 | |a text file |b PDF |2 rda | ||
| 490 | 1 | |a Contemporary Clinical Neuroscience, |x 2627-5341 | |
| 505 | 0 | |a Molecular Biomarkers.Somatic instability/Telomeres,- Genetic modifiers -- Current clinical trial biomarkers.-Pharmacodynamic biomarkers for Htt-lowering therapeutics.-Inflammatory biomarkers.-Sleep dysregulation markers.-Mitochondrial/Oxidative stress biomarkers.-Microbiomics -- Metabolomics.-Proteomics.-Transcriptomics.-Lipidomics.-Imaging marker overview.-Retinal imaging biomarkers -- MRI - non-invasive functional MRI measures -- The evolution of clinical trial methodology.-Digital biomarkers -- The future of telehealth -- Summary and future trends. | |
| 520 | |a Huntington’s disease (HD) is a fatal, inherited, neurodegenerative disorder, characterized by chorea, motor instabilities, psychiatric manifestations and cognitive decline. Early genetic testing provides an opportunity for clinical interventions aimed at delaying onset and/or slowing progression of disease; however, current treatments for HD are limited, with only two FDA-approved drugs available to manage chorea. Encouragingly, however, several disease-modifying treatment approaches are in the therapeutic pipeline, with more than 200 clinical studies, and many more preclinical studies, in the works. Robust and reliable biomarkers are needed to predict disease onset, monitor disease progression and assess treatment responses. More specifically, biomarkers to stratify patients for clinical trials and biomarkers to track drug efficacy will certainly lead to improved clinical trial design and success. This book represents the first book focused solely on biomarkers for HD and represents adistinct resource that will be informative, not only for clinicians and those involved in clinical trial design, but also for a wide range of neurodegenerative disease researchers. This edited volume is written by top leaders in the field, and takes a cross-disciplinary approach to cover a broad spectrum of biomarker types, in order to provide the latest advances in the development of biochemical, molecular, imaging and digital biomarkers that have been investigated for HD. With the ultimate goal of treating patients, the development of disease-associated biomarkers has never been more important. | ||
| 532 | 8 | |a Accessibility summary: This PDF does not fully comply with PDF/UA standards, but does feature limited screen reader support, described non-text content (images, graphs), bookmarks for easy navigation and searchable, selectable text. Users of assistive technologies may experience difficulty navigating or interpreting content in this document. We recognize the importance of accessibility, and we welcome queries about accessibility for any of our products. If you have a question or an access need, please get in touch with us at accessibilitysupport@springernature.com. | |
| 532 | 8 | |a No reading system accessibility options actively disabled | |
| 532 | 8 | |a Publisher contact for further accessibility information: accessibilitysupport@springernature.com | |
| 588 | |a Print version record. | ||
| 650 | 0 | |a Neurosciences. | |
| 650 | 0 | |a Neurology . | |
| 650 | 0 | |a Neurophysiology. | |
| 650 | 0 | |a Neuropharmacology. | |
| 650 | 1 | 4 | |a Neuroscience. |
| 650 | 2 | 4 | |a Neurology. |
| 650 | 2 | 4 | |a Neurophysiology. |
| 650 | 2 | 4 | |a Neuropharmacology. |
| 700 | 1 | |a Thomas, Elizabeth A. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Parkin, Georgia M. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 710 | 2 | |a SpringerLink (Online service) | |
| 773 | 0 | |t Springer Nature eBook | |
| 776 | 0 | 8 | |i Printed edition: |z 9783031328145 |
| 776 | 0 | 8 | |i Printed edition: |z 9783031328169 |
| 776 | 0 | 8 | |i Printed edition: |z 9783031328176 |
| 830 | 0 | |a Contemporary Clinical Neuroscience, |x 2627-5341 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-3-031-32815-2 |
| 912 | |a ZDB-2-SBL | ||
| 912 | |a ZDB-2-SXB | ||
| 950 | |a Biomedical and Life Sciences (SpringerNature-11642) | ||
| 950 | |a Biomedical and Life Sciences (R0) (SpringerNature-43708) | ||